AlzeCure Pharma AB (OSTO:ALZCUR) EV-to-EBIT : -3.61 (As of May. 27, 2024)

AlzeCure Pharma AB EV-to-EBIT Chart

AlzeCure Pharma AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															-4.74	-6.70	-5.69	-4.41	-2.51

Competitive Comparison of AlzeCure Pharma AB's EV-to-EBIT

For the Biotechnology subindustry, AlzeCure Pharma AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AlzeCure Pharma AB's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AlzeCure Pharma AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where AlzeCure Pharma AB's EV-to-EBIT falls into.

AlzeCure Pharma AB EV-to-EBIT Calculation

AlzeCure Pharma AB's EV-to-EBIT for today is calculated as:

AlzeCure Pharma AB's current Enterprise Value is kr135.10 Mil.
AlzeCure Pharma AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-37.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AlzeCure Pharma AB  (OSTO:ALZCUR) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

AlzeCure Pharma AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

AlzeCure Pharma AB's Enterprise Value for the quarter that ended in Mar. 2024 was kr93.96 Mil.
AlzeCure Pharma AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-37.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AlzeCure Pharma AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of AlzeCure Pharma AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

AlzeCure Pharma AB (OSTO:ALZCUR) Business Description